67377-44-0

Basic information

• Product Name: Benzenesulfonyl chloride, 4-(benzoylamino)-
• CAS NO: 67377-44-0
• Molecular Formula: C13H10ClNO3S
• Molecular Weight: 295.746
• Mol File: 67377-44-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzenesulfonyl chloride, 4-(benzoylamino)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfonyl chloride, 4-(benzoylamino)-(67377-44-0)
• EPA Substance Registry System: Benzenesulfonyl chloride, 4-(benzoylamino)-(67377-44-0)

Safety Data

• Hazardous Substances Data: 67377-44-0(Hazardous Substances Data)

Upstream product

• 93-98-1 N-phenyl benzoyl amide 
• 98-88-4 benzoyl chloride 
• 121-57-3 4-aminobenzene sulfonic acid 

Downstream Products

• 16803-97-7 p-aminobenzenesulphonamido-4-aniline 
• 19837-83-3 4-amino-N-(3-nitrophenyl)benzene-1-sulfonamide 
• 369-92-6 N-benzoyl-sulfanilic acid-(3,5-bis-trifluoromethyl-anilide) 
• 89565-06-0 C₁₃H₁₃N₃O₃S 
• 89565-13-9 4-Benzoylamino-benzenesulfonyl azide 
• 289638-64-8 FG 2032 
• 6267-28-3 N-(3-aminophenyl)-4-aminobenzenesulfonamide 
• 89565-10-6 C₂₀H₁₆N₄O₅S 
• 89565-11-7 C₂₁H₁₉N₃O₄S 
• 89565-14-0 N-[4-(3-Aza-tricyclo[3.2.1.0^2,4]octane-3-sulfonyl)-phenyl]-benzamide 
• 89565-09-3 C₂₀H₁₇N₃O₃S 
• 89565-12-8 C₁₉H₂₁N₃O₃S 
• 89565-08-2 C₁₆H₁₇N₃O₃S 
• 332108-36-8 isopropyl-BAPSG 

Relevant articles and documents

Design, synthesis and biological evaluation of suramin-derived dual antagonists of the proinflammatory G protein-coupled receptors P2Y2 and GPR17

Dual- or multi-target drugs are particularly promising for the treatment of complex diseases such as (neuro)inflammatory disorders. In the present study, we identified dual antagonists for two related pro-inflammatory G protein-coupled receptors (GPCRs), the purinergic receptor P2Y2 receptor, and the orphan receptor GPR17. Based on the lead compound suramin small molecules were designed, synthesized, and modified, including benzenesulfonate, benzenesulfonamide, dibenzamide and diphenylurea derivatives. Structure-activity relationship studies identified 3-nitrophenyl 4-benzamidobenzenesulfonic acid derivatives as dual P2Y2R/GPR17 antagonists. In particular, 3-nitrophenyl 4-(4-chlorobenzamido)benzenesulfonate (14l, IC50 3.01 μM at P2Y2R, and 3.37 μM at GPR17) and 3-nitrophenyl-4-(2-chlorobenzamido)benzenesulfonate (14m, IC50 3.17 μM at P2Y2R, and 1.67 μM at GPR17) exhibited dual antagonistic activity. Compound 14l was shown to act as an allosteric antagonist at both receptors. In addition, GPR17-selective antagonists were identified including 3-nitrophenyl 4-benzamidobenzenesulfonate (14a, IC50 3.20 μM) and 3-nitrophenyl 4-(3-(trifluoromethyl)benzamido)benzenesulfonate (14f, IC50 3.88 μM). The developed antagonists were selective versus other closely related P2Y receptors. They were found to possess high chemical and metabolic stability in human liver microsomes and therefore present good starting points for developing potent multi-target drugs with potential applications in inflammatory diseases.

Some Novel Sulfanilyl Derivatives

Benzoic acid anilide and p-chloro, m-nitro, together with the 2,4-, 2,5- and 3,4-dichloro derivatives, react with chlorosulfonic acid in 1:4 molar ratios to give the corresponding sulfanilyl chlorides.However, nicotinic acid and isonicotinic acid anilides react with chlorosulfonic acid in 1:6 molar ratios only for conversion into the sulfanilyl chlorides. 2,4-Dichlorophenoxyacetic acid anilide reacts with chlorosulfonic acid in 1:3 molar ratio to give the sulfanilyl chloride; this reaction when carried out in 1:7 molar ratios of the reactants affords the disulfonylchloride.The various sulfanilyl chlorides are reacted with amines, azide ion, and hydrazine to give a range of sulfonyl compounds.The compounds prepared have been subjected to preliminary biological screening.